• Lexaria Bioscience Corp LEXX.OQ reported a quarterly adjusted loss of 15 cents​​ per share for the quarter ended February 28, lower than the same quarter last year, when the company reported EPS of -6 cents. The mean expectation of two analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -17 cents to -14 cents per share.

• Revenue was $174.00 thousand​; analysts expected $137.00 thousand.

• Lexaria Bioscience Corp's reported EPS for the quarter was a loss of 15 cents​.

• The company reported a quarterly loss of $2.71 million.

• Lexaria Bioscience Corp shares had fallen by 21.1% this quarter and lost 35.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 40.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Lexaria Bioscience Corp is $7.50

This summary was machine generated from LSEG data April 14 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)